Abstracts tagged "autoimmune diseases"

Abstract Number: 1086 • ACR Convergence 2025
Leveraging Natural Language Processing to Uncover Real-World Trends in Cannabis Use from Clinic Notes in Electronic Health Records
Titilola Falasinnu¹, Nathan Le², Yiyu Wang², Aishwarya Alagappan², Michael Weisman³, Anushka Irani⁴, Yashaar Chaichian⁵ and Selen Bozkurt⁶, ¹Stanford School of Medicine, Palo Alto, CA, ²Stanford School of Medicine, Stanford, CA, ³Cedars-Sinai Medical Center, LOS ANGELES, CA, ⁴Mayo Clinic, Jacksonville, FL, ⁵Stanford University, Stanford, CA, ⁶Emory University School of Medicine, Atlanta, GA
Background/Purpose: Pain management in autoimmune rheumatic diseases (ARDs) increasingly includes NSAIDs, physical therapy, and self-management. However, the role of cannabis in ARD symptom relief remains…
Abstract Number: 0964 • ACR Convergence 2025
A Single-Cell Atlas Reveals Dermal Endothelial Heterogeneity and Disease-Specific Pathways in Autoimmune Disorders
Haoyu Pan¹, Jinyi Qian¹, Shuyi Yu¹, Zhixia Yang¹, Jason S. Knight², Eliza Tsou³ and Hui Shi⁴, ¹Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan; Ann Arbor, Michigan, USA., Ann Arbor, MI, ⁴Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: Autoimmune conditions with skin involvement, including scleroderma (SSc), antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and psoriasis (PSO), involve intricate interactions between immune cells…
Abstract Number: 0913 • ACR Convergence 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
Veronica Campbell¹, Yi Zhang¹, Virginia Massa¹, Jordan Leedberg¹, Erik Corcoran¹, Emily Lurier¹, Ryan Camire², Chris Carroll¹, Chris Ho¹, Dapeng Chen¹, Bradley Enerson¹, Revonda Mehovic¹, Ziyan Zhao¹, Lincoln Howarth¹, Susanne Breitkopf¹, Sarah Martinez¹, Melissa Ford¹, Xue Fei¹, Murugappan Sathappa¹, Juliet Williams³, Matthew Weiss³, Arsalan Shabbir³ and Nello Mainolfi⁴, ¹Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², ²Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², MA, ³Kymera Therapeutics, Watertown, ⁴Kymera Therapeutics, Watertown, MA
Background/Purpose: IRF5 is a transcription factor and regulator of immune responses activated downstream of pattern recognition receptors, in particular endosomal toll-like receptors (TLR), TLR7, TLR8…
Abstract Number: 0646 • ACR Convergence 2025
A-319, a CD3×CD19 T Cell Engager, for the Treatment of Refractory Systemic Lupus Erythematosus: Preliminary Evidence of Autoimmune Reset
Chunli Mei¹, Xin Guan¹, Rong Du¹, Bin Wu², You Song¹, Xiaoqi Chen³, Mengjiao Li¹, Xiaojing Liu¹, Xi Cheng¹, Weiwei Wang¹, Cheng Wang¹, Huiling Mei¹, Xiaoru Duan¹, Lijuan Jiang¹, Wenlin Qiu¹, Likai Yu¹, Yuhong Liu¹, Di Wu¹, Guiqi Quan¹, Blal Chakhabi¹, Xing Zhao⁴, Xuanfan Zhong⁴, Shengjie Xue⁴, Wuzhong Shen⁴, Ying Tan⁴, Guojian Yu⁴, Guiyun Tu⁴, Hanyang Chen⁴, Amy Sun⁴, Jing Liang⁴, Sharon Song⁴, Jason Xu⁴, Xiaoqiang Yan⁴, Anbing Huang¹ and Qiubai Li⁵, ¹Union Hospital,Tongji Medical College, Huazhong University of Science and Technology, WUHAN, China (People's Republic), ²First People’s Hospital of Jingzhou, Jingzhou, China (People's Republic), ³Zhongnan Hospital, Wuhan University, Wuhan, China (People's Republic), ⁴ITabMed Co., Ltd., Shanghai, China (People's Republic), ⁵Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic)

Background/Purpose: Immune reset of autoimmune disease has been proposed to be a potential benefit of T cell engagers (TCEs) and CD19 CAR T therapy. A-319,…
Abstract Number: 0856 • ACR Convergence 2025
Integrated Single-Cell and Spatial Transcriptomics Reveal Vascular and Immune Pathogenesis in APS Nephropathy
Shuyi Yu¹, Haoyu Pan¹, Jinyi Qian¹, Xiaohan Wei², Yuying Fan¹, Zhixia Yang¹, Shiyan Gu¹, Jianzhou Wu¹, Cenyi Wang¹, Tiancheng Zhou¹ and Hui Shi³, ¹Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ²Shanghai JiaoTong University, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To elucidate the molecular and cellular mechanisms underlying antiphospholipid antibody (aPL) nephropathy using integrated single-cell and spatial transcriptomic (SP) profiling of kidney tissues.Methods: Renal…
Abstract Number: 0372 • ACR Convergence 2025
Development and Implementation of a Remote Educational Program to Optimize Safe Medication Use in Older Veterans with Rheumatic Diseases
Maria Romero Noboa¹, Hannah Howell², Angelo Gaffo³ and Maria I. ("Maio") Danila⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ⁴University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Symptomatic treatment in rheumatic and musculoskeletal diseases (RMDs) – including glucocorticoids (GCs) and non-steroidal anti-inflammatory drugs (NSAIDs) – can result in improved quality of…
Abstract Number: 0271 • ACR Convergence 2025
Clinical Presentation of Igg4-Related Disease. Multicenter Study and Literature Review
Rafael Gálvez Sánchez¹, Fernando Lopez Gutierrez², Javier Loricera³, Pablo Martínez Calabuig⁴, Jorge Juan Fragío Gil⁵, Roxana González Mazario⁶, Cristina Hormigos Martin⁷, DALIFER FREITES⁸, Maria Rodriguez Laguna⁹, Patricia Moya Albarado¹⁰, Marta López i Gómez¹¹, Hector Corominas¹², Maite Silva-Diaz¹³, GUILLERMO GONZALEZ ARRIBAS¹⁴, Angel Garcia-Aparicio¹⁵, Judit Font-Urgelles¹⁶, Ivette Casafont-Solé¹⁶, elisabeth Castañeda¹⁷, Carolina Merino¹⁸, Raquel Zas¹⁹, Juan Molina-Collada²⁰, Sergio Rodríguez Montero²¹, Rafael B. Melero-González²², Eva Galíndez Agirregoikoa²³, Andrea Hernández²⁴, Lucia Pantoja²⁵, Ignacio Braña²⁶, Vega Jovaní²⁷, Elia Valls-Pascual²⁸, Natalia Mena Vázquez²⁹, Adela Gallego³⁰, Noelia Cabaleiro Raña³¹, Raul Veroz³², Mariano Andrés Collado³³, Santos Castañeda³⁴ and Ricardo Blanco³⁵, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Immunopathology Group -IDIVAL, Reumatología, Santander, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ⁵Hospital General Universitario, Valencia, Spain, ⁶Hospital General de Valencia, Valencia, Spain, ⁷Hospital Clínico San Carlos, Madrid, Spain, ⁸Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁹Hospital Clinico San Carlos, Madrid, Spain, ¹⁰Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹¹Hospital Universitario de Araba, Vitoria, Pais Vasco, Spain, ¹²Hospital de Sant Pau, Barcelona, Spain, ¹³Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, ¹⁴Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, ¹⁵Hospital Universitario de Toledo, Toledo, Spain, ¹⁶Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁷Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, ¹⁸Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain, ¹⁹Hospital Universitario Doce de Octubre, Madrid, Spain, ²⁰Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Spain, ²¹Hospital Universitario de Valme, Sevilla, Andalucia, Spain, ²²COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ²³BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ²⁴Hospital Universitario de Gran Canaria Dr Negrin, Palmas de Gran Canaria, Canarias, Spain, ²⁵Complejo Hospitalario Segovia, Segovia, Spain, ²⁶Hospital Universitario Central de Asturias, Oviedo, Spain, ²⁷Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ²⁸Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ²⁹Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ³⁰Complejo Hospitalario don Benito Villanueva, Badajoz, Spain, ³¹Hospital Universitario Montecelo, Rheumatology, Pontevedra, Galicia, Spain, ³²Hospital de Merida, Merida, Extremadura, Spain, ³³Hospital General Universitario de Alicante, Madrid, Comunidad Valenciana, Spain, ³⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ³⁵Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory entity that can involve almost every organ, with characteristic histological features. Its pathogenesis remains poorly understood, clinical…
Abstract Number: 0212 • ACR Convergence 2025
Biomarker-Guided Therapeutic Calculator for Personalized Management in Pregnant Patients with Autoimmune Rheumatic Diseases
Noe Macias-Segura¹, Rodolfo Martinez-Canales¹, Andres M. Ortiz-Rios², Braulio R. Avalos-Garcia², Eva Abigaid Galindo-Calvillo², Mario Cesar Salinas-Carmona¹, Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³ and Cassandra Michele Skinner-Taylor², ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Therapeutic decisions during pregnancy in women with autoimmune rheumatic diseases (ARDs) such as SLE, APS, RA, and Sjögren’s syndrome require a personalized approach due…
Abstract Number: 0083 • ACR Convergence 2025
Confirmatory Factor Analysis of the Plutchik Suicide Risk Scale in Patients with Rheumatoid Arthritis
Pedro Quevedo¹, Javier mora², william garcia², alejandra Solano², juliana Muñoz² and Daniela Lopez², ¹San Rafael Cinic University Hospital, Bogota, Distrito Capital de Bogota, Colombia, ²san rafael clinic universtity hospital, Bogota, Distrito Capital de Bogota, Colombia
Background/Purpose: Prevalence of depression in RA patients ranging from 10% to 25%, making it the most common psychiatric disorder in this population. The Plutchik Suicide…
Abstract Number: 0012 • ACR Convergence 2025
KT501, a CD19/BCMA/CD3 trispecific antibody, leads to rapid and deep B-cell depletion with well-tolerated safety
Min Bao, John Wang, Jay Zhao and Weihao Xu, Kali Therapeutics, San Mateo, CA
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19 or B-cell maturation antigen (BCMA) have shown unprecedented effects in treatment-resistant autoimmune diseases such as systemic…
Abstract Number: PP02 • ACR Convergence 2025
When The Body Speaks But No One Listens: A Dermatomyositis Story Through a Public Health Lens
Kyanna Johnson, Lynn Wilson, Manuel Lubinus, Elisa Glass
Background/Purpose: My journey with dermatomyositis (DM) began abruptly in July 2024, when I was hit by sudden, severe muscle weakness after a GI infection. I…
Abstract Number: 2595 • ACR Convergence 2025
Impact of Different Types of Physical Activity on Bone Health in Patients with Inflammatory Rheumatic Diseases: a Cross-Sectional Analysis from a Prospective Cohort Study
Edgar Wiebe¹, Claire-Felicia Liebich², Dörte Huscher³, Lien Meerkatt⁴, Andriko Palmowski⁵, Sandra Hermann¹, Burkhard Muche⁵, Zhivana Boyadzhieva², Gerhard Krönke⁶, Bernd Wolfarth² and FRANK BUTTGEREIT⁷, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁷Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Physical exercise helps maintain bone mineral density (BMD), prevent falls, and reduce fracture risk. Strength and weight-bearing exercises are particularly effective. However, individuals with…
Abstract Number: 2468 • ACR Convergence 2025
RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis
Saira Sheikh¹, Vimal Derebail¹, Natalie Grovner¹, Gaurav Gulati², Mehrdad Abedi³, Meghan Sise⁴, Matthew Frigault⁴, Christopher Palma⁵, Patrick Reagan⁵, Cuoghi Edens⁶, Satya Kosuri⁶, Caitlin Elgarten⁷, Jon Burnham⁸, Jonathan Hogan⁹, Yvonne White⁹, Carl diCasoli⁹, Rebecca Estremera⁹, Jenell Volkov⁹, Daniel Nunez⁹, Fatemeh Hadi-Nezhad¹⁰, Thomas Furmanak⁹, Jason Stadanlick⁹, Larissa Ishikawa⁹, Zachary Vorndran⁹, Alexandra Ellis⁹, Jazmean Williams⁹, Steve Flanagan⁹, Quynh Lam¹⁰, Samik Basu⁹, Raj Tummala¹⁰ and David Chang⁹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of California, Davis School of Medicine, Davis, CA, ³University of California, Davis School of Medicine, Davis, ⁴Massachusetts General Hospital, Boston, MA, ⁵University of Rochester, Rochester, NY, ⁶University of Chicago, Chicago, IL, ⁷Children's Hospital of Philadelphia, Philadelphia, PA, ⁸Children's Hospital of Philadelphia, Bryn Mawr, PA, ⁹Cabaletta Bio, Philadelphia, PA, ¹⁰Cabaletta Bio, Philadelphia
Background/Purpose: Current goals of treatment for systemic lupus erythematosus (SLE) are to achieve low disease state/remission, prevent flares, minimize organ damage, and decrease long-term morbidity…
Abstract Number: 2350 • ACR Convergence 2025
Multicenter study on the use of Upadacitinib: sex specific results in Spondyloarthritis
Guillermo Gonzalez Mozo de Rosales¹, Luis Maria Lopez-Dominguez², Nerea Alcorta-Lorenzo³, oihane ibarguengoitia Barrena⁴, David Montero⁵, Ana Ruibal Escribano⁶, estibaliz barastay Alberdi⁷, Jesus Alejandro Valero Jaimes⁸, Libe Ibarrola⁹, Paula Garcia Escudero¹⁰, Marta Lopez I Gomez¹¹, Eva Galindez Aguirregoicoa¹² and Maria Luz Garcia Vivar¹³, ¹Basurto University Hospital, Bilbao, Spain, ²Rheumatology Department, Donostia University Hospital., San Sebastián, Pais Vasco, Spain, ³Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁴Galdakao-Usansolo University Hospital, GALDAKAO, Spain, ⁵Galdakao-Usansolo University Hospital, Bilbao, Spain, ⁶Urduliz Hospital, Urduliz, Pais Vasco, Spain, ⁷Urduliz Hospital, Urduliz, Spain, ⁸Hospital Bidasoa, Irán, Spain, ⁹Galdakao-Usansolo University Hospital, Galdakao, ¹⁰H.U.Araba, Vitoria, ¹¹Araba University Hospital, Vitoria, Pais Vasco, Spain, ¹²Basurto University Hospital, Bilbao, Pais Vasco, Spain, ¹³Basurto Hospital, Bilbao, Spain
Background/Purpose: Upadacitinib (UPA) is a Janus Kinase inhibitor (JAKi) selective for JAK1, approved for the treatment of both Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA).…
Abstract Number: 2023 • ACR Convergence 2025
Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center
Carmen Secada-Gómez¹, Ligia Gabrie-Rodriguez², Hector Ulloa-Alvarado³, Giuliano Boselli⁴, Camilo Veloza-Morales⁵, Diana Prieto-Peña⁶, juan Irure-Ventura⁷, Marcos López-Hoyos⁸ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Servicio Cántabro de Salud, Atención Primaria, Santander, Spain, Santander, Cantabria, Spain, ⁴Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ⁵Rheumatology Division, Hospital Universitario Joan XXIII, Tarragona, Spain, Tarragona, Catalonia, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁷Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Cantabria, Spain, ⁸Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain
Background/Purpose: Anti-Ro52 antibodies are frequently detected in patients with systemic autoimmune rheumatic diseases (SARDs). Emerging evidence suggests a potential link between isolated anti-Ro52 positivity and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].